ADMA Biologics 3Q 2026: Revenue $141.1M, Net income $49.88M, EPS $0.22— 10-Q Summary

What happened

ADMA Biologics reported third-quarter 2026 revenue of $141.1 million, net income of $49.88 million and diluted earnings per share of $0.22. Compared with the prior-year quarter, those figures increased 5.1%, 36.9% and 46.7%, respectively. Nine-month revenue rose 2.4% to $380.0 million.

Confirmed

Global impact / market context

Higher revenue and profit per share indicate stronger reported results, while the different growth rates show profit rose faster than sales. For the business, ASCENIV growth and improved manufacturing yields may support output, but falling BIVIGAM sales and plasma revenue declines create offsets.

Analyst inference

Nine-month ASCENIV sales increased 27.5% to $325.1 million, while BIVIGAM sales fell 47.1%; the article attributes pressure partly to competitor pricing and industry distribution shifts. These opposing product trends make sustained growth and the production benefits important to future revenue.

Confirmed

What to watch

1. Check whether fourth-quarter and later ASCENIV sales grow as management expects; the article reports strong demand and says growth is expected to continue. Confirmed
2. Track whether BIVIGAM sales stabilize as competitor pricing and distribution shifts continue to pressure the product, potentially limiting revenue growth. Analyst inference
3. Assess whether the 20% or greater production-yield improvement sustains higher output, and whether that translates into sales while plasma supply remains adequate. Analyst inference

Evidence

• Original source link unavailable